What’s already known about this topic?
1. The shining limelight is on mirabegron, a novel beta-3 agonist approved for the management of OABS owing to its unique mechanism of action and lack of the troublesome adverse effect profile of the frequently utilized anti-cholinergic drugs.
2. The efficacy of mirabegron as an add on therapy for the management of residual storage symptoms in patients of BPH with associated OABS after the initial run in therapy with alpha blockers is already documented reasonably well in the published English literature.